This week's View focuses on three trials investigating whether alirocumab reduces death after an index acute coronary syndrome, whether lisinopril or carvedilol is superior to placebo at preventing left ventricular systolic dysfunction, and whether icosapent ethyl safely reduces cardiovascular events among patients with high triglycerides.

Subscribe on iTunes | Subscribe on Google Play

Keywords: EaglesEyeView, ACC Annual Scientific Session, ACC19, ACC18, AHA Annual Scientific Sessions, AHA18, Acute Coronary Syndrome, Angina, Unstable, Antibodies, Monoclonal, Anthracyclines, Atrial Fibrillation, Cholesterol, HDL, Cholesterol, LDL, Blood Pressure, Breast Neoplasms, Cardiomyopathies, Cardiotoxicity, Chemotherapy, Adjuvant, Cost-Benefit Analysis, Diabetes Mellitus, Dyslipidemias, Eicosapentaenoic Acid, Heart Failure, Heart Rate, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypertriglyceridemia, Hypolipidemic Agents, Lisinopril, Myocardial Infarction, Myocardial Ischemia, Myocardial Revascularization, Primary Prevention, Proprotein Convertases, Secondary Prevention, Stroke, Stroke Volume, Subtilisins, Triglycerides, Women, Arrhythmias, Cardiac, Metabolic Syndrome, Coronary Angiography

< Back to Listings